Encyclopedia of Pathology

Living Edition
| Editors: J.H.J.M. van Krieken

Sclerosing Adenosis

  • Gyula Pekar
Living reference work entry
DOI: https://doi.org/10.1007/978-3-319-28845-1_4734-1

Synonyms

Definition

SA is a lobulocentric proliferation of distorted acini around a central duct with preservation of myoepithelial cells, accompanied with varying degrees of epithelial atrophy and stromal fibrosis.

Clinical Features

  • Incidence: SA is often an incidental finding in breast tissue removed for other reasons. In autopsy studies performed on patients with no history of breast disease, the incidence of SA was in a range of 7–20%. The lesion is present in 12–28% of breast biopsies without cancer and in 5–7% of malignant biopsies.

  • Age: Most patients are in their forties and fifties with a peak in the 45–55 age group (34%), versus 28.3% of older women and 21.6% of women less than 45.

  • Sex: SA is predominant in women and more common in obese and in women using hormone replacement therapy and with a higher fibroglandular breast tissue density at mammography (>25%). Because of increased estrogen receptor (ER) expression observed compared with normal...

This is a preview of subscription content, log in to check access.

References and Further Reading

  1. Jensen, R. A., Page, D. L., Dupont, W. D., & Rogers, L. W. (1989). Invasive breast cancer risk in women with sclerosing adenosis. Cancer, 64, 1977–1983.CrossRefGoogle Scholar
  2. Nassar, A., Hoskin, T. L., Stallings-Mann, M. L., Degnim, A. C., Radisky, D. C., Frost, M. H., Vierkant, R. A., Hartmann, L. C., & Visscher, D. W. (2015). Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: A nested case-control study from the Mayo Benign Breast Disease Cohort. Breast Cancer Research and Treatment, 151, 89–97.CrossRefGoogle Scholar
  3. Pavlakis, K., Zoubouli, C., Liakakos, T., Messini, I., Keramopoullos, A., Athanassiadou, S., Kafousi, M., & Stathopoulos, E. N. (2006). Myoepithelial cell cocktail (P63+SMA) for the evaluation of sclerosing breast lesions. Breast, 15, 705–712.CrossRefGoogle Scholar
  4. Urban, J. A., & Adair, F. E. (1949). Sclerosing adenosis. Cancer, 2, 625–634.CrossRefGoogle Scholar
  5. Visscher, D. W., Nassar, A., Degnim, A. C., Frost, M. H., Vierkant, R. A., Frank, R. D., Tarabishy, Y., Radisky, D. C., & Hartmann, L. C. (2014). Sclerosing adenosis and risk of breast cancer. Breast Cancer Research and Treatment, 144, 205–212.CrossRefGoogle Scholar
  6. Winham, S. J., Mehner, C., Heinzen, E. P., Broderick, B. T., Stallings-Mann, M., Nassar, A., Vierkant, R. A., Hoskin, T. L., Frank, R. D., Wang, C., Denison, L. A., Vachon, C. M., Frost, M. H., Hartmann, L. C., Aubrey Thompson, E., Sherman, M. E., Visscher, D. W., Degnim, A. C., & Radisky, D. C. (2017). NanoString-based breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Research and Treatment, 166, 641–650.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division for Laboratory Medicine, Department of PathologyLund UniversityLundSweden